-
National Cooperative Crohn's Disease Study: results of drug treatment.
The response of active and quiescent Crohn's disease to prednisone, sulfasalazine, or azathioprine has been studied in 569 patients in a placebo-controlled, randomized, multicenter cooperative trial. The response of active symptomatic disease to prednisone or sulfasalazine was significantly better than to placebo. Response to azathioprine was better than to placebo, but the difference did not reach conventional levels of statistical significance. Patients with colonic involvement were especially responsive to sulfasalazine, and those with small bowel involvement were especially responsive to prednisone. Patients' drug therapy immediately before entry to the study significantly affected subsequent response. For patients with quiescent disease, none of the drugs was superior to placebo in prophylaxis against flare-up or recurrence. There is less than a 5% risk that a clinically significant prophylactic effect of any of the drug regimens was missed.
PMID: 38176 [PubMed - indexed for MEDLINE]
-
Cited by 59 PubMed Central articles
-
ReviewTreatment of inflammatory bowel disease: a review of medical therapy.
Kozuch PL, Hanauer SB.
World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
[World J Gastroenterol. 2008]
-
European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, et al.
Gut. 2006 Mar; 55 Suppl 1:i16-35.
[Gut. 2006]
-
High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance.
Towers R, Naftali T, Gabay G, Carlebach M, Klein A, Novis B.
Clin Exp Immunol. 2005 Aug; 141(2):357-62.
[Clin Exp Immunol. 2005]
- » See all...